Randomized Controlled Trial of CES for Fibromyalgia
NCT: NCT04115033 · COMPLETED
Brief Summary
Given recent increasing opioid-related deaths and evidence showing against the use of opioids for non-malignant chronic pain, there is growing need for non-narcotic pain management. Fibromyalgia is a difficult to treat chronic pain condition that is often treated with opioids despite existing evidence. The prevalence of fibromyalgia is increased among Veterans returning from the gulf war and is already a significant burden in senior Veterans who may have suffered with chronic pain for decades already. Many treatment options for fibromyalgia carry intolerable side effects. CES (Cranial Electrical Stimulation) is a FDA-approved, non-pharmacologic therapy that is currently utilized within the military and VA system, but sufficient evidence regarding its outcomes and neural mechanisms have not been adequately investigated. An understanding of its neural underpinnings and analgesic effects could lead to 1) improvements in pain management and quality of life, 2) cost-savings and 3) development of new techniques to address pain.
Frequently Asked Questions
What is Randomized Controlled Trial of CES for Fibromyalgia?
Randomized Controlled Trial of CES for Fibromyalgia is a clinical trial registered under NCT04115033. Current status: COMPLETED.
What is the status of NCT04115033?
The current status of NCT04115033 (Randomized Controlled Trial of CES for Fibromyalgia) is: COMPLETED.
When did Randomized Controlled Trial of CES for Fibromyalgia start?
Randomized Controlled Trial of CES for Fibromyalgia started on 2020-03-02.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.